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Introduction
For a clinical test based on next generation sequencing (NGS) 
to be approved for use, its performance with respect to accuracy, 
analytical sensitivity, analytical specificity and precision, must 
be evaluated1–4. Analytical sensitivity refers to the ability of a 
sequencing test to detect real sequence variation. The evalua-
tion of analytical sensitivity therefore relies on the availability 
of gold-standard, validated, benchmarking datasets. For NGS 
analysis the availability of suitable datasets has been limited. Most 
laboratories undertake small scale evaluations, using in-house 
data that seldom comprehensively covers the spectra of variant 
types the test must detect5,6. Many laboratories also rely on 
in silico generated datasets to evaluate the performance of NGS 
variant detection pipelines. Whilst of value, in silico data cannot 
completely replace experimental data generated from biological 
samples that have been orthogonally validated7.
Cancer predisposition genes (CPGs), such as BRCA1 and BRCA2, 
are amongst the most widely tested genes in clinical practice6,8–10. 
Hundreds of providers across the world are now offering CPG 
testing using NGS methods, either through panel, exome, or 
whole genome testing9. Increasingly, the analysis of the data is 
processed separately to the generation of data and the clinical 
reporting of results, sometimes through outsourcing data analysis 
to a separate provider. This makes assessments and comparisons 
of analytical sensitivity even more challenging.
We have conducted CPG testing in research and clinical settings 
for over a decade, identifying many hundreds of pathogenic 
variants. We have generated extensive sequence-based data on 
thousands of samples using a variety of technologies including 
NGS methods, PCR amplification with Sanger sequencing, stand-
ard Multiplex Ligation-dependent Probe Amplification (MLPA), 
MLPA by NGS and Conformation Sensitive Gel Electrophoresis 
(CSGE). To validate the analytical sensitivity of our ISO 15189 
accredited CPG NGS clinical testing pipeline, we used data 
from 639 individuals known to have pathogenic variants in CPGs 
through testing by other methods. This validation resource has 
proved invaluable for ensuring optimal analytical sensitivity 
during the initial and ongoing development of our NGS pipelines.
To assist those without access to extensive validated datasets 
we have put together the ICR639 CPG NGS validation series, 
which we present here.
The ICR639 CPG NGS validation series comprises data from 
639 individuals. Each individual has sequencing data gener-
ated using the TruSight Cancer Panel (TSCP), a targeted NGS 
assay for the analysis of CPGs11, together with orthogonally 
generated data showing the presence of at least one CPG patho-
genic variant per individual. The set consists of 645 pathogenic 
variants in total. There is strong representation of the most chal-
lenging types of variants, with 339 indels, including 16 complex 
indels and 24 with length greater than five base pairs and 74 exon 
copy number variations (CNVs) including 23 single exon CNVs 
(Table 1). The series includes pathogenic variants in 31 CPGs. 
There are 502 pathogenic variants in BRCA1 or BRCA2, making 
this an important comprehensive validation dataset for providers 
of BRCA1 and BRCA2 NGS testing. The vast majority of variants 
occur in extremely high-quality sequencing data, fulfilling a 
Quality Sequencing Minimum (QSM) of C50_B10(85)_M20(95)12. 
As such, it is anticipated that any accredited test provider will be 
able to detect these variants.
The dataset size and comprehensive representation of variant 
types that can be detected by targeted sequencing, makes the 
ICR639 CPG NGS validation series a valuable benchmarking 
resource for providers of CPG testing by NGS. The dataset may 
also be of value to laboratories analysing other genes, and those 
performing exome or genome testing which will encompass 
CPGs. The ICR639 CPG NGS validation series was constructed 
as part of the Transforming Genetic Medicine Initiative (TGMI, 
www.thetgmi.org) a Wellcome funded initiative that is developing 
frameworks and resources to facilitate genetic medicine.
Methods
We used lymphocyte DNA from 639 individuals. The individuals 
were either recruited to our studies to discover and character-
ise disease predisposition genes, which have been approved 
by the London Multicentre Research Ethics Committee 
(05/MRE02/17, MREC/01/2/044, MREC/01/2/18), or from the 
TGLclinical laboratory, an ISO 15189 accredited genetic testing 
laboratory. Written informed consent from patients tested through 
TGLclinical includes use of samples for quality-control and 
research.
We generated high-quality targeted NGS data for the ICR639 
CPG NGS validation series using the TruSight Cancer Panel 
(TSCP) v2 (Supporting File 1). We prepared targeted DNA 
libraries from 50ng genomic DNA using the TSCP and TruSight 
Rapid Capture kit (Illumina, San Diego, CA, USA). We followed 
the manufacturer’s protocol with the exception of library enrich-
ment pool complexity, which we performed in 48-plex. For every 
sample, we sequenced a final 10pM pooled library on a HiSeq 
2500 platform set in Rapid-run mode following standard 
protocols: 96-plex pool per flow cell, HiSeq® Rapid SBS Kit v2, 
101 bp paired-end dual index run, and onboard clustering using 
HiSeq® Rapid PE Cluster Kit v2. CASAVA v.1.8.2 was used to 
demultiplex and create FASTQ files per sample from the raw base 
call files.
To evaluate data quality, we mapped the sequencing reads to the 
human reference genome (GRCh37) using Stampy v.1.0.2013 
with BWA v.0.7.5a14 for pre-mapping. We used CoverView 
v.1.1.015 to flag fragments containing the pathogenic variant, 
which did not fulfil a QSM12 of C50_B10(85)_M20(95) for all 
base substitutions and indels. All samples with an exon CNV 
pathogenic variant passed the default settings of DECoN 
v.1.0.016.
All 639 individuals also had orthogonally generated data 
available. These data were generated through either PCR ampli-
fication with Sanger sequencing17, standard MLPA or MLPA by 
NGS11,18.
Annotation of base substitutions and indels follows Clinical 
Sequencing Notation (CSN) v.1.019 using the RefSeq mRNA tran-
scripts. For all genes except WT1 the coding annotation (c.) starts 
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APC 2 1 1 0 0 4
ATM 3 1 1 0 1 6
BRCA1 85 102 24 3 30 244
BRCA2 86 120 30 11 11 258
BRIP1 4 4 3 0 0 11
CDH1 1 0 0 0 0 1
CDKN2A 2 1 0 0 0 3
CHEK2 0 2 0 0 4 6
DICER1 1 0 2 1 0 4
EPCAM 0 0 0 0 1 1
FH 2 0 0 0 1 3
GPC3 1 0 0 0 0 1
HRAS 1 0 0 0 0 1
MEN1 1 0 1 0 0 2
MLH1 4 1 2 0 1 8
MSH2 4 1 1 0 8 14
MSH6 6 2 3 0 2 13
MUTYH 1 0 0 0 0 1
NF1 1 2 0 0 1 4
PALB2 6 9 3 0 1 19
PMS2 2 1 0 0 4 7
PTEN 2 2 1 0 1 6
RAD51C 3 0 0 0 1 4
RAD51D 2 1 1 0 0 4
RB1 0 0 0 0 1 1
RET 3 0 0 0 0 3
SDHB 1 0 0 0 2 3
SDHD 1 0 0 0 0 1
SMARCB1 2 0 0 0 0 2
TP53 2 0 0 1 3 6
WT1 3 0 0 0 1 4
at 1, the A of the ATG translation initiation codon. For WT1, c.1 
is the A of the first in-frame AUG translation initiation codon and 
the KTS exon 9 sequence is included. We used Ensembl ENST 
transcripts from release 65 for exon CNV annotation as RefSeq 
mRNA transcripts do not specify intron/exon boundaries. All 
exon CNVs are described using the following notation “Exon 
X deletion/duplication” for single exon CNVs and “Exon X-Y 
deletion/duplication” for exon CNVs involving more than one 
exon, where X specifies the number of the first exon involved in 
the exon CNV with respect to the transcript, Y specifies the number 
of the last exon involved in the exon CNV with respect to the 
transcript, and deletion or duplication is specified as appropriate. 
For all genes except BRCA1 exon numbering is consecutive 
from the first non-coding exon in the transcript. For BRCA1 we 
use the conventional clinical numbering system that does not 
include exon 4.
We provide the left-aligned CHR, POS, REF and ALT informa-
tion according to GRCh37 for base substitutions and indels to 
allow comparison with Variant Calling Format (VCF) files. All 
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exon CNVs were validated by MLPA. We provide the most 5’ and 
most 3’ genomic coordinates of the exons involved in the exon 
CNV according to the exon numbering of the specified transcript. 
Of note, these are not the actual breakpoints; standardly neither 
MLPA nor targeted NGS data provides breakpoint sequence 
information for exon CNVs.
Dataset
The ICR639 CPG NGS validation series includes data from 
639 individuals. Six individuals have two different pathogenic 
variants, so the dataset contains a total of 645 pathogenic CPG 
variants (Supporting File 2). The pathogenic variants occur in 
31 different genes that are all proven disease-causing genes and 
are routinely tested in clinical practice6,8–10. The series includes 
502 pathogenic variants in BRCA1 or BRCA2, which are the most 
commonly tested CPGs, and 43 pathogenic variants in the Lynch 
syndrome genes (MLH1, MSH2, MSH6, PMS2 and EPCAM).
All 645 pathogenic CPG variants are different and together 
they cover the variant types routinely detected and reported in 
clinical genetic testing (Table 1). There are 232 base substitu-
tions, 323 insertions or deletions, 16 complex indels and 74 exon 
CNVs. Of note, the set include 24 insertions or deletions with 
length greater than five base pairs and 23 single exon CNVs, two 
challenging variant classes to detect in NGS data.
The ICR639 CPG NGS validation series comprises high qual-
ity sequencing data. For 561 of the 571 base substitutions and 
indels (98%), the fragment containing the variant fulfilled a 
QSM of C50_B10(85)_M20(95)12. This represents a minimum 
quality requirement whereby 100% of bases in the fragment had 
at least 50x depth of coverage with a base quality score of ≥10 
in at least 85% of reads and a mapping quality score of ≥20 in at 
least 95% of reads. For the remaining ten pathogenic variants, the 
fragment containing the variant did not meet the QSM requirement 
for either the base quality (n=5) or the mapping quality (n=5). All 
fragments fulfilled the coverage requirement. We include these 
variants to allow evaluation of variant detection performance 
in data with suboptimal base or mapping quality, as such data is 
commonly encountered in genetic testing. The sequencing data 
for all 74 exon CNVs fulfilled the minimum quality requirements 
of DECoN, a batch-based exon CNV calling tool16, namely a 
minimum correlation of 0.98 with other samples in its batch and 
a minimum median coverage metric of 100 across all exons in the 
target. The ICR639 CPG NGS validation series is thus a high- 
quality sequencing dataset and users are expected to detect all 
pathogenic variants in CPG(s) of relevance to their pipeline.
We have previously made freely available other datasets that 
groups may find useful in conjunction with the ICR639 CPG 
NGS validation series. For example, we generated TSCP data for 
the NIST-led Genome in a Bottle (GIAB) Consortium reference 
material (RM) 839815,20. We have also made available the ICR142 
exome validation series17 and ICR96 exon CNV validation 
series11. These resources allow evaluation of both sensitivity and 
specificity, for small variants and exon CNVs respectively. Of 
note, 50 exon CNVs are included in both the ICR96 exon CNV 
validation series and the ICR639 CPG NGS validation series.
Data availability
We have deposited the TSCP FASTQ files for all 639 individuals 
in the European Genome-phenome archive (EGA). The acces-
sion number is EGAS00001002993. Details of how to access the 
data is available at EGA or from www.icr.ac.uk/icr639.
The individual level genetic data on EGA is under managed 
access in line with general recommendations for use of patient 
information, the specific consent obtained for use of data from 
these samples and our institutional data access committee. The 
ICR-GSR data access application form should be completed 
and returned to rahmanlab@icr.ac.uk. Applications will only 
be accepted electronically. Access to the data will require the 
completion of a Data Access Agreement. Any queries regarding 
access procedures or completion of the forms should be sent to 
rahmanlab@icr.ac.uk.
Supporting data files have been archived on Open Science 
Framework: http://doi.org/10.17605/OSF.IO/N2VWR21 under a 
CC0 1.0 Universal licence.
-    Supporting File 1. TSCP targeted BED file. Targets of 
the Illumina TruSight Cancer Panel (TSCP) v2 in BED file 
format.
-    Supporting File 2. Pathogenic variants in the ICR639 
CPG NGS validation series. The ICR639 CPG NGS 
validation series: a resource to assess analytical sensitivity 
of cancer predisposition gene testing
The description of the column headings are given below:
-    SampleID – sample ID in the ICR639 CPG NGS validation 
series
-    AnnotationTranscript – the transcript used to annotate the 
variant, either the RefSeq NM ID or the Ensembl v65 ENST 
ID
-    Gene – HGNC symbol
-    ReportedVariant – Base substitutions and indels are in 
accordance with CSN v.1.0. Exon CNVs are described 
with notation “Exon X deletion/duplication” for single 
exon CNVs and “Exon X-Y deletion/duplication” for 
multi-exon CNVs, where X is the first exon and Y the last 
exon involved and deletion/duplication as appropriate
-    VariantType – “bs”, “del”, “ins”, “complex”, or “exonCNV” 
for base substitutions, deletions, insertions, complex indels, 
or exon CNV variants, respectively
-    Zygosity – “heterozygous” a pathogenic variant that is 
present on only one allele
-    AdjacentVariant – annotation according to CSN v.1.0 if a 
variant was detected adjacent to the reported variant, “.” if 
no adjacent variant was detected
-    QSMFragmentResult – “PASS” if the fragment contain-
ing the variant fulfilled QSM C50_B10(85)_M20(95), 
“FLAG – BaseQuality” if at least one position in the 
fragment containing the variant did not fulfil B10(85), 
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“FLAG – MappingQuality” if at least one position in the 
fragment containing the variant did not fulfil M20(95), “.” if 
the variant was an exon CNV
-    CHR – chromosome
-    POS – the left-aligned position in GRCh37 coordinates, “.” 
if the variant was an exon CNV
-    REF – the reference allele in GRCh37, “.” if the variant was 
an exon CNV
-    ALT – the alternative allele, “.” if the variant was an exon 
CNV
-    5PrimeExon37 – most 5’ genomic coordinate of most 
5’ exon in GRCh37
-    3PrimeExon37 – most 3’ genomic coordinate of most 
3’ exon in GRCh37
Researchers and authors that use the ICR639 CPG NGS 
validation series should reference this paper and should include 
the following acknowledgement: “This study makes use of the 
ICR639 CPG NGS validation series data generated by Professor 
Nazneen Rahman’s team at The Institute of Cancer Research, 
London as part of the TGMI”.
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